Search
Aldoxorubicin
go.drugbank.com/drugs/DB06013InvestigationalAldoxorubicin, an antineoplastic agents, is an albumin-binding prodrug of doxorubicin.
gamma-Butyrolactone
go.drugbank.com/drugs/DB04699ExperimentalIllicitIt is an endogenous compound made from gamma-aminobutyrate and is the precursor of gamma-hydroxybutyrate. It is also used as a pharmacological agent and solvent.
Categories: Compounds used in a research, industrial, or household settingAlbinterferon Alfa-2B
go.drugbank.com/drugs/DB05396InvestigationalIn response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug. … The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C.
Midomafetamine
go.drugbank.com/drugs/DB01454IllicitInvestigationalAn N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. … It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.
Fluoroazomycin arabinoside F-18
go.drugbank.com/drugs/DB15134InvestigationalFluoroazomycin arabinoside F-18 is under investigation in clinical trial NCT03257150 (A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer).
Categories: Compounds used in a research, industrial, or household settingSitamaquine
go.drugbank.com/drugs/DB04909InvestigationalSitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential
Bavituximab
go.drugbank.com/drugs/DB05136InvestigationalAdditional analogs in the class include 3G4, 2aG4, 9d2 and Hu3g4.
Sulfabenzamide
go.drugbank.com/drugs/DB09355ApprovedWithdrawnSulfabenzamide is an antimicrobial agent often used in conjunction with sulfathiazole and sulfacetamide as a topical intravaginal antibacterial preparation.
Synonyms: N-Benzoylsulfanilamide, N-SulfanilylbenzamideAmilomotide
go.drugbank.com/drugs/DB05150InvestigationalCAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease. … It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients.
Mivebresib
go.drugbank.com/drugs/DB21300InvestigationalMivebresib has a monoisotopic molecular weight of 459.11 Da. … Mivebresib is under investigation in clinical trial NCT04480086 (Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants